PDS Biotechnology is a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology platform. The Versamune® platform effectively delivers tumor-specific antigens for in-vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent tumor-specific killer T-cells. Using Versamune®, PDS Biotechnology is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors. PDS Biotechnology’s pipeline combines the Versamune® technology with tumor-specific antigens across several cancer types.

ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and peripheral inflammatory diseases.

FreiMc, comprised of senior healthcare executives, provides contract strategy and business development services to existing companies, as well as launches new, innovative businesses in the healthcare space.New Business formation: • CEO of EmployRx – A technology and service company, established by FrieMc, which reduces the cost of prescription drug benefits for self-insured employers.• CareTracker Partners - A strategic entity formed to establish a network of channel partners to promote and distribute the nation's leading cloud-based electronic medical record.

Axogen is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products used across various applications and surgical specialties, including traumatic injuries, oral and maxillofacial surgery, breast reconstruction, and the surgical treatment of pain. Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance Nerve Graft®, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector™, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to enhance nerve gliding and provide short- and long-term protection for peripheral nerve injuries; Avive+ Soft Tissue MatrixTM, a multi-layer amniotic membrane allograft used to protect and separate tissues in the surgical bed during the critical phase of tissue repair; and Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma.

LecTec, now AxoGen, Inc., was a public intellectual property (“IP”) licensing and holding company. It held multiple domestic and international patents based on its original hydrogel patch technology and had also filed patent applications for a hand sanitizer patch. It also had a licensing agreement with Novartis Consumer Health, Inc., which paid royalties to LecTec. LecTec took legal action as necessary to protect its IP. Its primary focus was pursuing a merger/acquisition strategy with the intent to leverage its cash asset and public company status, which strategy it completed through a reverse merger with AxoGen Corporation.

Pfizer Health Solutions Inc (PHS) was a wholly owned subsidiary of Pfizer Inc, the world's largest health care company. Through PHS, Pfizer created and evaluated positive examples of constructive health system renovation that could lead to widespread adoption and structural changes in health care around the world. PHS operated programs in the United States, the United Kingdom and Italy through its offices in New York and Europe. Major efforts included identifying, modeling and developing new projects, strategic partnerships and alliances. I was responsible for identifying and working with PHS projects to formalize their structure, identify and/or negotiate with necessary third parties, work through funding issues and finalizing agreements. Sample projects included Pfizer’s employee health initiative (over 45,000 employees), California adherence projects, MEDCO Collaboration, CMS Senior Risk Reduction Program, Staying Healthy USA, Healthier Florida and Allscripts Collaboration.

Guidant Corporation designed and developed cardiovascular medical products. Its CRM division represented the significant portion of its worldwide operations. A long term plan of CRM was focused on the convergence of medical devices, diagnostics, biotechnology and information technologies. My major responsibilities included review and development of the biotechnology and diagnostic component of the convergence plan, transaction execution and extension of Guidant’s opportunity network.

HTS was a private corporation which developed next-generation, high-throughput bio-analytical systems and related consumables for the proteomics, biodefense and medical diagnostic markets. HTS developed and launched internationally the FLEXCHIP Kinetic Analysis System and sold its product line to its major competitor.

Quantech was a public company developing a medical diagnostic system which obtained FDA approval of its detection system and first test.

Practiced law in the areas of general corporate, securities, mergers and acquisitions in a diverse number of industries from. Focused on start-up and emerging growth companies with a specialty in investment banking activity having been involved in an extensive number of public, private and merger transactions from both the company and banking side.